Literature DB >> 23834524

Serum levels of tenascin-C in collagen diseases.

Kuniko Inoue1, Masatoshi Jinnin, Yumiko Hara, Katsunari Makino, Ikko Kajihara, Takamitsu Makino, Keisuke Sakai, Satoshi Fukushima, Yuji Inoue, Hironobu Ihn.   

Abstract

Tenascins are a family of large multimetric extracellular matrix (ECM) proteins. Among them, large molecular weight variant tenascin-C is known to be specifically expressed in pathological conditions. However, no link between tenascin-C and collagen diseases has been established. The aim of our study was to determine the serum tenascin-C levels in patients with various collagen diseases, and to evaluate the possibility that serum levels of tenascin-C can be a useful marker for collagen diseases, correlating with the pathogenesis. Serum tenascin-C levels of 33 patients with scleroderma (SSc), 10 patients with scleroderma spectrum disorder (SSD), 15 patients with localized scleroderma (LSc), 12 patients with dermatomyositis (DM), 10 patients with systemic lupus erythematosus (SLE) and 15 healthy controls were measured with specific enzyme-linked immunosorbent assays. Serum tenascin-C levels were significantly elevated in patients with SSc, SSD and LSc than in healthy controls. Significantly higher total skin thickness score or higher incidence of pitting scars/ulcers and diffuse pigmentation were observed in SSc patients with elevated tenascin-C levels than in those with normal levels. Our study suggests that serum tenascin-C levels are increased in fibrotic conditions, and that tenascin-C contributes to the pathogenesis of vascular damage as well as fibrosis in SSc patients. Clarifying the role of tenascin-C in the pathogenesis of collagen diseases may lead to a new therapeutic approach.
© 2013 Japanese Dermatological Association.

Entities:  

Keywords:  autoimmune disease; dermatomyositis; fibrosis; scleroderma; systemic lupus erythematosus

Mesh:

Substances:

Year:  2013        PMID: 23834524     DOI: 10.1111/1346-8138.12218

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  6 in total

Review 1.  Tenascins in fibrotic disorders-from bench to bedside.

Authors:  M Kasprzycka; C Hammarström; G Haraldsen
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

2.  Tenascin C in radiation-induced lung damage: Pathological expression and serum level elevation.

Authors:  Yutaka Toyomasu; Kenta Matsui; Kazuki Omori; Akinori Takada; Kyoko Imanaka-Yoshida; Isao Tawara; Akira Shimamoto; Motoshi Takao; Hiroyasu Kobayashi; Atsushi Tomaru; Hajime Fujimoto; Tetsu Kobayashi; Haiime Sakuma; Yoshihito Nomoto
Journal:  Thorac Cancer       Date:  2022-09-01       Impact factor: 3.223

Review 3.  Revisiting the matricellular concept.

Authors:  Joanne E Murphy-Ullrich; E Helene Sage
Journal:  Matrix Biol       Date:  2014-07-24       Impact factor: 11.583

Review 4.  Emerging Roles of Matricellular Proteins in Systemic Sclerosis.

Authors:  Daniel Feng; Casimiro Gerarduzzi
Journal:  Int J Mol Sci       Date:  2020-07-06       Impact factor: 5.923

5.  Clinical significance and prognosis of serum tenascin-C in patients with sepsis.

Authors:  Weifang Yuan; Wei Zhang; Xiaofang Yang; Liyuan Zhou; Ziwei Hanghua; Kailiang Xu
Journal:  BMC Anesthesiol       Date:  2018-11-15       Impact factor: 2.217

6.  Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.

Authors:  Jakub Závada; Michal Uher; Radka Svobodová; Marta Olejárová; Markéta Hušáková; Hana Ciferská; Hana Hulejová; Michal Tomčík; Ladislav Šenolt; Jiří Vencovský
Journal:  Arthritis Res Ther       Date:  2015-11-25       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.